Therapeutic Potential of Micheliolide and ACT001 in Age-Related Diseases: Molecular Mechanisms and Clinical Prospects
aging and disease · 2026
DOI: 10.14336/ad.2025.1556 ↗Kurz gefasst
Fachartikel in der Zeitschrift aging and disease, 2026. Verfasst von Hui Xu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, Peking University First Hospital, Beijing 100034, China.
Abstract (Originalsprache)
Aging is the predominant risk factor for several chronic disorders; therefore, elucidating the molecular and cellular mechanisms underlying age-related pathologies is essential for therapeutic advancement. Micheliolide (MCL), a naturally occurring guaianolide sesquiterpene lactone derived from Michelia champaca and Michelia compressa, has attracted increasing attention for its pharmacological potential. Its derivative, ACT001, enables the sustained release of MCL into the plasma in vivo, thereby enhancing oral bioavailability and improving therapeutic efficacy. ACT001 has recently received orphan drug designation for glioblastoma treatment, highlighting its clinical feasibility and safety profile. Increasing evidence indicates that MCL regulates age-related diseases by modulating inflammation, cell cycle, mitochondrial dysfunction, oxidative stress, and autophagy. By targeting key signaling pathways, including NF-κB, STAT3, NRF2, AMPK, and NLRP3, MCL/ACT001 demonstrated its protective effect against age-related diseases. This paper summarizes the current mechanistic insight and disease-specific evidence regarding MCL/ACT001 and further evaluates their therapeutic repositioning potential for age-related diseases, including cardiovascular and cerebrovascular diseases, fibrotic conditions, immune disorders, metabolic diseases, and tumors. Additionally, we discussed key translational challenges.
Autor:innen und Institutionen
- Department of Geriatrics, Peking University First Hospital, Beijing 100034, China.
- Department of Physiology and Pathophysiology, Peking University School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, Beijing 100191, China.
Zitieren
APA
Xu, H., Cong, X., & Lin, L. J. (2026). Therapeutic Potential of Micheliolide and ACT001 in Age-Related Diseases: Molecular Mechanisms and Clinical Prospects. aging and disease. https://doi.org/10.14336/ad.2025.1556
Vancouver
Xu H, Cong X, Lin LJ. Therapeutic Potential of Micheliolide and ACT001 in Age-Related Diseases: Molecular Mechanisms and Clinical Prospects. aging and disease. 2026. doi:10.14336/ad.2025.1556
BibTeX
@article{Xu2026,
author = {Xu, Hui and Cong, Xin and Lin, Lian-Jun},
title = {Therapeutic Potential of Micheliolide and ACT001 in Age-Related Diseases: Molecular Mechanisms and Clinical Prospects},
journal = {aging and disease},
year = {2026},
doi = {10.14336/ad.2025.1556}
}
EUVIMED